Evidence map›Paper›PMID 35889532›Full record

ReviewMolecules (Basel, Switzerland)2022

Involvement of Resveratrol against Brain Cancer: A Combination Strategy with a Pharmaceutical Approach.

Chenmala Karthika, Agnieszka Najda, Joanna Klepacka, Mehrukh Zehravi, Rokeya Akter, Muhammad Furqan Akhtar, Ammara Saleem, Majed Al-Shaeri, Banani Mondal, Ghulam Md Ashraf and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

Chenmala KarthikaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India.ORCID 0000-0001-7874-6521
Agnieszka NajdaDepartment of Vegetable and Herbal Crops, University of Life Science in Lublin, Doświadczalna Street 51A, 20280 Lublin, Poland.ORCID 0000-0002-1185-8884
Joanna KlepackaDepartment of Commodity Science and Food Analysis, Faculty of Food Science, University of Warmia and Mazury in Olsztyn, Oczapowskiego 2, 10719 Olsztyn, Poland.ORCID 0000-0001-5871-635X
Mehrukh ZehraviDepartment of Clinical Pharmacy Girls Section, Prince Sattam Bin Abdul Aziz University, Alkharj 11942, Saudi Arabia.
Rokeya AkterDepartment of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju 26426, Korea.
Muhammad Furqan AkhtarRiphah Institute of Pharmaceutical Sciences, Lahore Campus, Riphah International University, Lahore 54950, Pakistan.ORCID 0000-0003-2270-6242
Ammara SaleemDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad 38000, Pakistan.
Majed Al-ShaeriDepartment of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Banani MondalDepartment of Pharmacy, Ranada Prasad Shaha University, Narayanganj 1400, Bangladesh.
Ghulam Md AshrafPre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-9820-2078
Priti TagdeAmity Institute of Pharmacy, Amity University, Noida 201301, India.ORCID 0000-0002-0375-9165
Sarker RamproshadDepartment of Pharmacy, Ranada Prasad Shaha University, Narayanganj 1400, Bangladesh.ORCID 0000-0001-9277-2451
Zubair AhmadUnit of Bee Research and Honey Production, Faculty of Science, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.
Farhat S KhanBiology Department, College of Arts and Sciences, Dehran Al-Junub, King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.
Md Habibur RahmanDepartment of Global Medical Science, Wonju College of Medicine, Yonsei University, Wonju 26426, Korea.ORCID 0000-0001-6099-5693
King Abdulaziz University · SAKing Khalid University · SAYonsei University · KRAmity University · INGovernment College University, Faisalabad · PKJSS Academy of Higher Education and Research · INPrince Sattam Bin Abdulaziz University · SARiphah International University · PKUniversity of Life Sciences in Lublin · PLUniversity of Warmia and Mazury in Olsztyn · PL

Funding

Minister of Education and Science 010/RID/2018/19
6 · The paper itself

Abstract

A brain tumor (BT) is a condition in which there is growth or uncontrolled development of the brain cells, which usually goes unrecognized or is diagnosed at the later stages. Since the mechanism behind BT is not clear, and the various physiological conditions are difficult to diagnose, the success rate of BT is not very high. This is the central issue faced during drug development and clinical trials with almost all types of neurodegenerative disorders. In the first part of this review, we focus on the concept of brain tumors, their barriers, and the types of delivery possible to target the brain cells. Although various treatment methods are available, they all have side effects or toxic effects. Hence, in the second part, a correlation was made between the use of resveratrol, a potent antioxidant, and its advantages for brain diseases. The relationship between brain disease and the blood-brain barrier, multi-drug resistance, and the use of nanomedicine for treating brain disorders is also mentioned. In short, a hypothetical concept is given with a background investigation into the use of combination therapy with resveratrol as an active ingredient, the possible drug delivery, and its formulation-based approach.

Indexed as

Brain NeoplasmsStilbenesAntioxidantsBrainDrug Delivery SystemsHumansPharmaceutical PreparationsResveratrolAntioxidantsPharmaceutical PreparationsResveratrolStilbenesantioxidantsblood–brain barrierbrain tumornasal deliveryP-glycoproteinresveratrol

Identifiers

PMID35889532
PMCPMC9320031
OpenAlexW4286434094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.